DDInter1532 DDInter1676
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Promazine {u} (Compound) resembles {v} (Compound) Propiomazine
Promazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Promazine {u} (Compound) binds {v} (Gene) ADRA2A
Promazine {u} (Compound) upregulates {v} (Gene) EBP
Promazine {u} (Compound) downregulates {v} (Gene) EZH2
Promazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Promazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promazine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Promazine (Compound) resembles Propiomazine (Compound)
Promazine (Compound) resembles Ethopropazine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Promazine (Compound) binds ADRA2A (Gene)
Promazine (Compound) upregulates EBP (Gene)
Promazine (Compound) downregulates EZH2 (Gene)
Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Promazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promazine may lead to a major life threatening interaction when taken with Bupropion